Recent Innovations in Precision Oncology: The Pathway toward a Patient-Tailored Approach
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 1877
Special Issue Editor
Interests: FDG PET/CT; oncology; therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Precision oncology has been gaining more and more consideration in the scientific community and represents one of most impactful revolutions in medicine. In recent decades, the approach to disease has thoroughly changed, passing from the idea that the same drug might work sufficiently well for different patients to the concept of tailoring treatment on the basis of patients’ individual biological and molecular characteristics. In this scenario, molecular diagnostics through recently introduced techniques, such as next-generation sequencing (NGS), has become an essential tool for a rapid and accurate analysis of oncological patients’ genetic profile when molecularly targeted therapies are planned. On the other side, molecular imaging through different techniques (SPECT/CT, PET/CT, optical imaging) has been employed in the field of precision oncology for the in vivo detection of tumor-associated biomarkers, also in the perspective of combining diagnosis and in therapy in a unique approach, also known as “theranostics”. For example, the use of PET radioligands targeting prostate specific membrane antigen (PSMA) has been applied with overwhelming results for the management of prostate cancer. Finally, the emerging applications of artificial intelligence (A) and “radiomics” hold the promise to move the field of precision oncology forward by extrapolating information from image intensity, shape, and texture through sophisticated mathematical tools.
In the present Special Issue, we solicit original research or review articles highlighting the potential and emerging applications of novel technologies in precision oncology, with a particular focus on novel molecular probes for molecular imaging and on the still few explored applications of AI and radiomics.
Prof. Dr. Luca Filippi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- precision medicine
- oncology
- molecular imaging
- molecular biology
- theranostics
